CELL-FREE REGENERATIVE MEDICINE: Nano-Engineered "LIFNano" to treat Multiple Sclerosis

纳米医学（NanoMed）是医学的一个新时代，它利用纳米工程在正确的时间、正确的地点提供正确剂量的治疗。LIF是一种对维持大脑健康很重要的生长因子，SME“LNT”开创了NanoMed将LIF作为治疗破坏性自身免疫性疾病多发性硬化症（MS）的革命性方法。多发性硬化症是一种无法治愈的疾病，它会侵袭大脑，始于成年初期，每年给全球经济造成约1000亿美元的损失。目的：在证明了LIFNano （LN001）远远优于MS的最佳替代疗法之后，该项目现在将在两个方面向患者提供LN001:(i)通过建立NanoMed的第一个英国商业资源；（ii）在临床配方中加入LN001。三个层面的协同作用：英国制造，拥有LNT全球独家许可的英国知识产权，以及以英国为基地的ms新治疗方法的全球领导者。英国经济的收益将很高，随着大型制药公司的参与，特别是因为LN001适用于广泛的退行性疾病，I-UK对LNT的支持的附加价值将超过100倍。进一步的附加价值是在英国的高价值制造弹射器（CPI）增加的专业投资组合。

NANOMEDICINE (NanoMed) is a new era in medicine that exploits nano-engineering to deliver the right dose of therapy to the right place, at the right time. LIF is a growth factor important for maintaining brain health and the SME "LNT" has pioneered NanoMed for delivery of LIF as a revolutionary approach to treat the devastating autoimmune disease MULTIPLE SCLEROSIS (MS). Incurable, MS attacks the brain, starting in young adulthood and costing the global economy some $100bn pa. AIMS: having proven LIFNano (LN001) is far superior to the best alternative therapy for MS, this project will now deliver LN001 to patients on two fronts: (i) by establishing the first UK-based commercial resource for NanoMed; and (ii) by securing LN001 in a clinical formula. Three levels of synergy operate: UK manufacture, UK intellectual property with worldwide exclusive licence to LNT, and UK-based global leader in new therapeutic approaches to MS. The gain to the UK economy will be high and the added value of I-UK support to LNT will exceed 100-fold on licencing as Big Pharma become engaged especially since LN001 is applicable to a wide range of degenerative conditions. Further added value is in the increased specialist portfolio of UK's High Value Manufacturing Catapult (CPI).